Ritonavir News and Research

RSS

Ritonavir, also known as Norvir, is a type of medicine called a protease inhibitor (PI). PIs act by blocking protease, a protein that HIV needs to make more copies of itself. Ritonavir was approved by the FDA on March 1, 1996, for use with other antiretroviral agents in the treatment of HIV infection in adults and children 2 years of age or older. Ritonavir is now approved with other anti-HIV drugs in the treatment of HIV-1 infection in children in individuals over 1 month in age. Studies have shown that ritonavir works as a booster for some other PIs. Taking ritonavir makes it possible to take a lower dose of the other PIs. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.

SARS-CoV-2 Mpro inhibitors built on rattlesnake venom scaffold

A new study describes the development of new molecules with inhibitory activity against the SARS-CoV-2 viral main protease (Mpro) enzyme, based on rattlesnake venom.

29 Apr 2022

Thousands more vulnerable patients are eligible to receive the UK’s second antiviral for COVID-19

Thousands more vulnerable people in England are now eligible to receive the UK's second oral antiviral treatment for Covid.

12 Apr 2022

Challenges, unmet needs and future opportunities in COVID-19 therapeutics

In a recent article published in the journal Proceedings of the National Academy of Sciences (PNAS), researchers reviewed the present-day therapeutic landscape of coronavirus disease 2019 (COVID-19) and addressed future opportunities to overcome challenges that hinder drug development and improve the global preparedness for future pandemics.

10 Apr 2022

Study explores broad-spectrum, host-acting antiviral strategy to treat SARS-CoV-2

A new study investigates the combination of two small molecules that target the host cells and reports a synergistic antiviral activity in vitro against SARS-CoV-2.

7 Apr 2022

Value of information analysis on clinical trial data to help approve or reject new COVID-19 drugs

Researchers quantified the cost-effective health benefits of pursuing further research or approving or rejecting COVID-19 drugs based on the existing research using a novel method called VOI analysis.

4 Apr 2022

An in-depth analysis of pathogenesis of SARS-CoV-2 and therapeutic options for COVID-19

Scientists discuss the pathogenic characteristics of SARS-CoV-2 and available therapeutic interventions for treating COVID-19.

3 Apr 2022

HIV patients on antiretroviral treatment with protease inhibitors may have lower COVID-19 risk

A preliminary study to be presented at this year's European Congress of Clinical Microbiology & Infectious Diseases in Lisbon, Portugal (23-26 April), suggests that people living with HIV who are on antiretroviral treatment (ART) with protease inhibitors (PI), may have a lower risk of COVID-19 infection.

27 Mar 2022

Early treatment of COVID-19 in high-risk children and adolescents infected with the Omicron variant of SARS-CoV-2

Researchers discussed patient features, treatment-associated process measures, and outcomes associated with early monoclonal antibody and antiviral therapy in high-risk pediatric patients infected with the SARS-CoV-2 Omicron variant.

22 Mar 2022

Study results in three new co-amorphous drug systems with great anti-COVID-19 potential

Researchers demonstrated that the bioavailability of matrine-type alkaloids could be prolonged by employing a co-former, resveratrol.

15 Mar 2022

Further optimization of cysteine-reactive pyrazoline-based covalent inhibitors for the SARS-CoV-2 Mpro

Researchers discovered and optimized cysteine-reactive pyrazoline-based covalent inhibitors for several coronaviruses' Mpro, including SARS-CoV-2.

11 Mar 2022

Exploring biomedical literature and clinical trial records to identify new drug combinations for COVID-19 treatment

Researchers extensively searched publicly available SARS-CoV-2 biomedical literature to identify drug combinations that could effectively treat COVID-19.

7 Mar 2022

WHO experts suggest antiviral drug for patients with non-severe covid-19 at highest risk of hospitalization

The antiviral drug molnupiravir is conditionally recommended for patients with non-severe covid-19 who are at highest risk of hospitalization, says a WHO Guideline Development Group of international experts in The BMJ today.

3 Mar 2022

Identifying and managing drug-drug interactions key to the safe use of nirmatrelvir–ritonavir in COVID-19 treatment

Researchers compiled evidence-based recommendations in consultation with European and North American clinicians and pharmacologists for recognizing and managing drug-drug interactions with nirmatrelvir–ritonavir.

3 Mar 2022

Study explores the decline in viral load and immune response in COVID-19 patients

Researchers described the changes in viral ribonucleic acid the decline in viral load, and the immune response of SARS-CoV-2-infected patients, in a new preprint study.

22 Feb 2022

SARS-CoV-2 Mpro inhibitor, nirmatrelvir, found to reduce COVID-19 progression and death

In a new study, researchers evaluated the efficacy and safety of nirmatrelvir in mild to moderate COVID-19 patients who were at high risk of severe COVID-19 disease.

18 Feb 2022

Trial of early antiviral therapy for COVID-19 shows no significant benefit

A new preprint research paper examines the efficacy of using three antivirals in various combinations in early infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Feb 2022

Phase one study of oral SARS-CoV-2 antiviral agent nirmatrelvir

A recent study posted to the medRxiv* preprint server reported the phase one pharmacokinetic and safety data of nirmatrelvir/ritonavir to facilitate its rapid progression to the last stages of clinical trials in coronavirus disease 2019 (COVID-19) patients with mild to moderate disease.

14 Feb 2022